Zika Virus Vaccine Market

The Zika Virus Vaccine Market  is valued at USD 18.11 Billion in 2021 and is expected to reach USD 25.22 Billion by 2028 with a CAGR of 4.84% over the forecast period.

Global Zika Virus Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027, Increasing investment by government and private organization in research & development, technological advancement, high prevalence of zika virus infection are anticipated to grow the global zika virus market.

Zika Virus Vaccine Market Scope

Zika virus belongs to the Flaviviridae family, which is mostly related to the dengue, yellow fever, west Nile virus and Japanese encephalitis. Zika is enveloped, positive sense single stranded RNA virus. Zika virus is primarily spread by the bite of female aedes aegypti mosquito to humans which are active in daytime. Zika has been detected in many species of Aedes, along with Mansonia uniformis, Anopheles coustani, and Culex perfuscus. Symptoms of zika virus are conjunctivitis, general malaise, fever, skin rashes, and joint pain. The zika virus vaccine is made to prevent infection and complication of virus in humans. In April 1947, the first virus was isolated from a rhesus macaque monkey which was placed inside cage in the Zika forest of Uganda. The name zika is given in 1948 when a monkey developed fever and researchers isolated from its serum a filterable transmissible agent.

COVID-19 pandemic has shown the negative impact on the global zika virus vaccine market. The extensive and sudden outbreak of coronavirus has overshadowed other developing bacterial and viral threats such as Zika flavivirus. Moreover, the disturbance in supply chain and availability of workforce has contributed to the negative impact in manufacturing the zika virus vaccine. According to the worldometer, the confirmed cases of corona virus are 263,198,304 and death confirmed were 5,236,535 till 1st Dec’2021.

Zika Virus Vaccine Market Key Players

Global zika virus vaccine market report cover prominent players like

• GeneOne Life Science Inc
• Moderna Inc
• NewLink Genetics Co.
• Immunovaccine Inc
• Takeda Pharmaceutical Co. Ltd.
• GlaxoSmithKline plc.
• Bharat Biotech International Ltd.
• Inovio Pharmaceuticals Inc
• Themis Bioscience GmbH
• Valneva Austria GmbH
• NHI
• Sanofi
• Inovio Pharmaceuticals
• PaxVax
• Gilead Sciences Inc
• Intrexon Corp
• NewLink Genetics Corp others.

Zika Virus Vaccine Market Segmentation

Global Zika Virus vaccine market is segmented on the basis of type, end user, region and country level. Based on the type the global market is classified into preventive vaccine, therapeutics vaccine and other. Based on the end user the global market is classified into clinics, hospitals, research institutes and others.

By Type:

• Preventive Vaccine
• Therapeutics Vaccine
• Other

By End User:

• Clinics
• Hospitals
• Research Institutes
• Others 

Increasing investment by government and private organization in research & development, technological advancement in vaccination is anticipated the growth of global zika virus market

The main factors that boost the global zika virus vaccine market is high incidence of zika virus infection. For instance, according to the WHO, 2015 report Brazil reported outbreak evidence of transmission throughout Americas, Africa, and other regions of the world. 86 countries and territories have reported evidence of mosquitoes transmitted zika infection. Furthermore, increasing investment by the governments, institution and key companies are also expected to contribute the market growth. The Europe has invested around 45 million euros in research to fight against the emerging zika virus. The three consortia to fight against zika virus are zika plan, zika action and zika alliance. According to the global biosecurity, the cases that confirmed in the year 2016, 2017, 2018 and 2019 are 81,852; 607; 1800; and 15 cases respectively.

Another factor that drives the market is technological advancement in vaccination, NIAID is developing a multi vaccine candidate to prevent zika virus infection which is DNA based. In August 2016 the phase 1 trial started, and in 2017 phase 2 clinical trial of the candidate known as VRC 705. On the other hand, NIAID VRC is also working with the GlaxoSmithKline (GSK), Moderna/Valera and University of Pennsylvania to evaluate various mRNA vaccine technologies to identify scalable candidates and immunogenic. For further development the London based pharmaceutical company SEEK has collaborated with the hVIVO, this will prevent and protect against multiple mosquito- borne diseases, including Zika. However, lack of knowledge regarding vaccines and infections including the unavailability of technology in undeveloped countries are likely to hamper the market growth. On the other hand, investment done by the key players for further research along with untapped opportunities from the developing economies are likely to crate ample opportunities in the market.

Latin America holds the largest market share in the Global Zika Virus Vaccine Market.

Based on geography the market is classified into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Latin America is expected to dominate the market growth owing to the high incidence rate of zika virus as compared to the other regions. For instance, according to the Brazilian authorities, since 2014, over 1,638 babies have been born with microcephaly-related defects if women are infected with the virus during pregnancy, and almost 100,000 people were conformed with the Zika virus infection. The due to the high incidence rate the government authorities of Brazil have declared zika virus infection as epidemic. Additionally, to deal with such situations various research programs are conducted by government in collaboration with organizational bodies such as WHO. According to WHO, new evidence is published by recipients of a joint small grant programs which is funded by the TDR and HRP with support from PAHO. Also, these projects have proved that how essential they are to build a strong community-based research in high- and low-income countries. 

The regions covered in this global zika virus vaccines market report is North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East, GCC (UAE, Saudi Arabia, Kuwait) Africa, etc.

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA 

News:

World first needle free zika virus vaccine for USD 1.35 million

September 3rd, 2020: Researcher at the University of Adelaide have awarded for 1.35 million USD to accelerate the development of world first zika virus vaccine. The researchers main aim to develop a novel needle free vaccine to prevent pregnant women from the infection and rule out the possibility of congenital effects in the unborn child. This novel formulation is developed in collaboration with the Enesi Pharma, Oxford UK and has combined zika virus DNA vaccine with the ImplaVax technology of Enesi Pharma. This technology will deliver a single solid dose that implant through the skin into tissue without needle. This vaccine formulation will be more effective, and will provide significant benefits to patient, and healthcare professionals. It also needs minimal training for use and can eliminates the need of cold chain storage. 

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2017 - 2027
Market Size in 2021:	USD 18.11 Billion
Base year considered	2020
Forecast Period CAGR %:	4.84%
Market Size Expected in 2028:	USD 25.22 Billion
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	GeneOne Life Science, Inc, Moderna Inc, NewLink Genetics Co., Immunovaccine Inc, Takeda Pharmaceutical Co. Ltd., GlaxoSmithKline plc., Bharat Biotech International Ltd., Inovio Pharmaceuticals, Inc, others.
Segments Covered	By Type, By End User.
Regional Analysis	North America, U.S., Canada, , Europe, Germany, France, U.K., Italy, Spain, Sweden, Netherland, Turkey, Switzerland, Belgium, Rest of Europe, Asia-Pacific, South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC, Latin America, Mexico, Colombia, Brazil, Argentina, Peru, Rest of South America, Middle East and Africa, Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA